Diabetic gastroparesis-Backwards and forwards

Journal of Gastroenterology and Hepatology (Australia)

Volumn 26, Issue SUPPL. 1, 2011, Pages 46-57

  Chang, Jessica ^a,b   Rayner, Christopher K ^a,b   Jones, Karen L ^a,b   Horowitz, Michael ^a,b  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b Centre of Clinical Research Excellence in Nutritional Physiology   (Australia)

Author keywords

Blood glucose; Diabetes; Gastric emptying; Incretin hormones

Indexed keywords

ACOTIAMIDE; ALCOHOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BOTULINUM TOXIN; CALCIUM CHANNEL BLOCKING AGENT; CANNABIS; CHOLINERGIC RECEPTOR BLOCKING AGENT; CISAPRIDE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DOMPERIDONE; ERYTHROMYCIN; EXENDIN 4; GASTRIC INHIBITORY POLYPEPTIDE; GHRELIN; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INCRETIN; INSULIN; LEVODOPA; LIRAGLUTIDE; METOCLOPRAMIDE; NICOTINE; OCTREOTIDE; OPIATE; ORAL ANTIDIABETIC AGENT; PRAMLINTIDE; SEROTONIN 4 AGONIST;

ABDOMINAL PAIN; ADD ON THERAPY; BARIUM MEAL; BLOATING; BREATH ANALYSIS; DIABETES MELLITUS; DIABETIC GASTROPARESIS; DIABETIC PATIENT; DIABETOGENESIS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FATALITY; DRUG PENETRATION; DRUG SAFETY; ECHOGRAPHY; ELECTROGASTROGRAPHY; ELECTROSTIMULATION; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART DEATH; HEART VENTRICLE ARRHYTHMIA; HORMONE ACTION; HORMONE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; INSULIN TREATMENT; MANOMETRY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; POSTPRANDIAL STATE; PREVALENCE; PRIORITY JOURNAL; QT PROLONGATION; REVIEW; SIDE EFFECT; STOMACH EMPTYING; STOMACH PARESIS; STOMACH SCINTISCANNING; TACHYPHYLAXIS; TARDIVE DYSKINESIA; TELEMETRY; VOMITING;

EID: 78650770743     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2010.06573.x     Document Type: Review

References (115)

1. Rundles RW. Diabetic neuropathy; general review with report of 125 cases. Medicine 1945; 24: 111-60.
2. Horowitz M, Harding PE, Maddox A et al. Gastric and oesophageal emptying in insulin-dependent diabetes mellitus. J. Gastroenterol. Hepatol. 1986; 1: 97-113.
3. Wingate DL. Backwards and forwards with the migrating complex. Dig. Dis. Sci. 1981; 26: 641-66.
4. Horowitz M, Jones KL, Akkermans LM et al. Gastric function. In: Horowitz M, Samson M, eds. Gastrointestinal Function in Diabetes Mellitus. Chichester: John Wiley & Sons Ltd, 2004; 117-76.
5. Horowitz M, Dent J. Disordered gastric emptying: mechanical basis, assessment and treatment. Baillieres Clin. Gastroenterol. 1991; 5: 371-407.
6. Fried M, Erlacher U, Schwizer W et al. Role of cholecystokinin in the regulation of gastric emptying and pancreatic enzyme secretion in humans. Studies with the cholecystokinin-receptor antagonist loxiglumide. Gastroenterology 1991; 101: 503-11.
7. Deane AM, Nguyen NQ, Stevens JE et al. Endogenous glucagon-like peptide-1 slows gastric emptying in healthy subjects, attenuating postprandial glycemia. J. Clin. Endocrinol. Metab. 2010; 95: 215-21.
8. Lin HC, Doty JE, Reedy TJ, Meyer JH. Inhibition of gastric emptying by glucose depends on length of intestine exposed to nutrient. Am. J. Physiol. 1989; 256: G404-11.
9. Camilleri M. Integrated upper gastrointestinal response to food intake. Gastroenterology 2006; 131: 640-58.
10. Boas I. Diseases of the Stomach, 9th edn. Leipzig: Georg Thieme, 1925.
11. Ferroir J. The Diabetic Stomach. Thesis in Medicine. Paris, France, 1937.
12. Saltzman MB, McCallum RW. Diabetes and the stomach. Yale J. Biol. Med. 1983; 56: 179-87.
13. Kassander P. Asymptomatic gastric retention in diabetics (gastroparesis diabeticorum). Ann. Intern. Med. 1958; 48: 797- 812.
14. Horowitz M, Harding PE, Maddox AF et al. Gastric and oesophageal emptying in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1989; 32: 151-9.
15. Samsom M, Vermeijden JR, Smout AJ et al. Prevalence of delayed gastric emptying in diabetic patients and relationship to dyspeptic symptoms: a prospective study in unselected diabetic patients. Diabetes Care 2003; 26: 3116-22.
16. Horowitz M, Maddox AF, Wishart JM, Harding PE, Chatterton BE, Shearman DJ. Relationships between oesophageal transit and solid and liquid gastric emptying in diabetes mellitus. Eur. J. Nucl. Med. 1991; 18: 229-34.
17. Jones KL, Horowitz M, Wishart MJ, Maddox AF, Harding PE, Chatterton BE. Relationships between gastric emptying, intragastric meal distribution and blood glucose concentrations in diabetes mellitus. J. Nucl. Med. 1995; 36: 2220-8.
18. Parkman HP, Camilleri M, Farrugia G et al. Gastroparesis and functional dyspepsia: excerpts from the AGA/ANMS meeting. Neurogastroenterol. Motil. 2010; 22: 113-33.
19. Bharucha AE, Camilleri M, Forstrom LA, Zinsmeister AR. Relationship between clinical features and gastric emptying disturbances in diabetes mellitus. Clin. Endocrinol. (Oxf) 2009; 70: 415-20.
20. Horowitz MHP, Maddox A, Maddern GJ, Chatterton BE, Wishart J, Shearman DJC. Gastric and oesophageal emptying in insulin-dependent diabetes mellitus. J. Gastroenterol. Hepatol. 1986; 1: 97-113.
21. Kong MF, Horowitz M, Jones KL, Wishart JM, Harding PE. Natural history of diabetic gastroparesis. Diabetes Care 1999; 22: 503-7.
22. Jones KL, Russo A, Berry MK, Stevens JE, Wishart JM, Horowitz M. A longitudinal study of gastric emptying and upper gastrointestinal symptoms in patients with diabetes mellitus. Am. J. Med. 2002; 113: 449-55.
23. Camilleri M, Hasler WL, Parkman HP, Quigley EM, Soffer E. Measurement of gastrointestinal motility in the GI laboratory. Gastroenterology 1998; 115: 747-62.
24. Johnson RD, Horowitz M, Maddox AF, Wishart JM, Shearman DJ. Cigarette smoking and rate of gastric emptying: effect on alcohol absorption. BMJ 1991; 302: 20-3.
25. Abell TL, Camilleri M, Donohoe K et al. Consensus recommendations for gastric emptying scintigraphy: a joint report of the American Neurogastroenterology and Motility Society and the Society of Nuclear Medicine. J. Nucl. Med. Technol. 2008; 36: 44-54.
26. Viramontes BE, Kim D-Y, Camilleri M et al. Validation of a stable isotope gastric emptying test for normal, accelerated or delayed gastric emptying. Neurogastroenterol. Motil. 2001; 13: 567-74.
27. Haruma K, Kusunoki H, Manabe N et al. Real-time assessment of gastroduodenal motility by ultrasonography. Digestion 2008; 77 (Suppl 1): 48-51.
28. Gentilcore D, Hausken T, Horowitz M, Jones KL. Measurements of gastric emptying of low- and high-nutrient liquids using 3D ultrasonography and scintigraphy in healthy subjects. Neurogastroenterol. Motil. 2006; 18: 1062-8.
29. Gilja OH, Hausken T, Degaard S, Berstad A. Gastric emptying measured by ultrasonography. World J. Gastroenterol. 1999; 5: 93-4.
30. Hveem K, Jones KL, Chatterton BE, Horowitz M. Scintigraphic measurement of gastric emptying and ultrasonographic assessment of antral area: relation to appetite. Gut 1996; 38: 816-21.
31. Stevens JE, Gilja OH, Gentilcore D et al. Validation of 3D ultrasonography to measure gastric emptying of a high-nutrient drink in diabetic gastroparesis (abstract). Gastroenterology 2008; 134: A340.
32. Willems M, Quartero AO, Numans ME. How useful is paracetamol absorption as a marker of gastric emptying? A systematic literature study. Dig. Dis. Sci. 2001; 46: 2256-62.
33. Camilleri M, Bharucha AE, di Lorenzo C et al. American Neurogastroenterology and Motility Society consensus statement on intraluminal measurement of gastrointestinal and colonic motility in clinical practice. Neurogastroenterol. Motil. 2008; 20: 1269-82.
34. Koch KL. Electrogastrography: physiological basis and clinical application in diabetic gastropathy. Diabetes Technol. Ther. 2001; 3: 51-62.
35. Jebbink RJ, Samsom M, Bruijs PP et al. Hyperglycemia induces abnormalities of gastric myoelectrical activity in patients with type I diabetes mellitus. Gastroenterology 1994; 107: 1390-7.
36. Ewing DJ, Clarke BF. Diagnosis and management of diabetic autonomic neuropathy. Br. Med. J. (Clin. Res. Ed.) 1982; 285: 916-18.
37. Buysschaert M, Moulart M, Urbain JL et al. Impaired gastric emptying in diabetic patients with cardiac autonomic neuropathy. Diabetes Care 1987; 10: 448-52.
38. Ma J, Rayner CK, Jones KL, Horowitz M. Diabetic gastroparesis: diagnosis and management. Drugs 2009; 69: 971-86.
39. Pasricha PJ, Pehlivanov ND, Gomez G, Vittal H, Lurken MS, Farrugia G. Changes in the gastric enteric nervous system and muscle: a case report on two patients with diabetic gastroparesis. BMC Gastroenterol. 2008; 8: 21.
40. He CL, Soffer EE, Ferris CD, Walsh RM, Szurszewski JH, Farrugia G. Loss of interstitial cells of cajal and inhibitory innervation in insulin-dependent diabetes. Gastroenterology 2001; 121: 427-34.
41. Samsom M, Akkermans LM, Jebbink RJ, van Isselt H, vanBerge-Henegouwen GP, Smout AJ. Gastrointestinal motor mechanisms in hyperglycaemia induced delayed gastric emptying in type I diabetes mellitus. Gut 1997; 40: 641-6.
42. Choi KM, Kashyap PC, Dutta N et al. CD206-positive M2 macrophages that express heme oxygenase-1 protect against diabetic gastroparesis in mice. Gastroenterology 2010; 138: 2399-409.
43. Forster J, Damjanov I, Lin Z, Sarosiek I, Wetzel P, McCallum RW. Absence of the interstitial cells of Cajal in patients with gastroparesis and correlation with clinical findings. J. Gastrointest. Surg. 2005; 9: 102-8.
44. Watkins CC, Sawa A, Jaffrey S et al. Insulin restores neuronal nitric oxide synthase expression and function that is lost in diabetic gastropathy. J. Clin. Invest. 2000; 106: 803.
45. Choi KM, Gibbons SJ, Nguyen TV et al. Heme oxygenase-1 protects interstitial cells of Cajal from oxidative stress and reverses diabetic gastroparesis. Gastroenterology 2008; 135: 2055-64. 64: e1-2.
46. Kashyap PC, Choi KM, Dutta N et al. Carbon monoxide reverses diabetic gastroparesis in NOD mice. Am. J. Physiol. Gastrointest. Liver Physiol. 2010; 298: G1013-19.
47. Bharucha AE, Kulkarni A, Choi KM et al. First-in-human study demonstrating pharmacological activation of heme oxygenase-1 in humans. Clin. Pharmacol. Ther. 2010; 87: 187-90.
48. Rayner CK, Samsom M, Jones KL, Horowitz M. Relationships of upper gastrointestinal motor and sensory function with glycemic control. Diabetes Care 2001; 24: 371-81.
49. Fraser RJ, Horowitz M, Maddox AF, Harding PE, Chatterton BE, Dent J. Hyperglycaemia slows gastric emptying in type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1990; 33: 675-80.
50. Schvarcz E, Palmer M, Aman J, Horowitz M, Stridsberg M, Berne C. Physiological hyperglycemia slows gastric emptying in normal subjects and patients with insulin-dependent diabetes mellitus. Gastroenterology 1997; 113: 60-6.
51. Schvarcz E, Palmer M, Aman J, Berne C. Hypoglycemia increases the gastric emptying rate in healthy subjects. Diabetes Care 1995; 18: 674-6.
52. Schvarcz E, Palmer M, Aman J, Lindkvist B, Beckman KW. Hypoglycaemia increases the gastric emptying rate in patients with type 1 diabetes mellitus. Diabet. Med. 1993; 10: 660-3.
53. Russo A, Stevens JE, Chen R et al. Insulin-induced hypoglycemia accelerates gastric emptying of solids and liquids in long-standing type 1 diabetes. J. Clin. Endocrinol. Metab. 2005; 90: 4489-95.
54. Bytzer P, Talley NJ, Leemon M, Young LJ, Jones MP, Horowitz M. Prevalence of gastrointestinal symptoms associated with diabetes mellitus: a population-based survey of 15 000 adults. Arch. Intern. Med. 2001; 161: 1989-96.
55. Schvarcz E, Palmer M, Ingberg CM, Aman J, Berne C. Increased prevalence of upper gastrointestinal symptoms in long-term type 1 diabetes mellitus. Diabet. Med. 1996; 13: 478-81.
56. Talley NJ, Young L, Bytzer P et al. Impact of chronic gastrointestinal symptoms in diabetes mellitus on health-related quality of life. Am. J. Gastroenterol. 2001; 96: 71-6.
57. Jones KL, Horowitz M, Carney BI, Wishart JM, Guha S, Green L. Gastric emptying in early noninsulin-dependent diabetes mellitus. J. Nucl. Med. 1996; 37: 1643-8.
58. Samsom M, Salet GA, Roelofs JM et al. Compliance of the proximal stomach and dyspeptic symptoms in patients with type I diabetes mellitus. Dig. Dis. Sci. 1995; 40: 2037-42.
59. Kumar A, Attaluri A, Hashmi S, Schulze KS, Rao SS. Visceral hypersensitivity and impaired accommodation in refractory diabetic gastroparesis. Neurogastroenterol. Motil. 2008; 20: 635-42.
60. Rayner CK, Verhagen MA, Hebbard GS, DiMatteo AC, Doran SM, Horowitz M. Proximal gastric compliance and perception of distension in type 1 diabetes mellitus: effects of hyperglycemia. Am. J. Gastroenterol. 2000; 95: 1175-83.
61. Hebbard GS, Samsom M, Sun WM, Dent J, Horowitz M. Hyperglycemia affects proximal gastric motor and sensory function during small intestinal triglyceride infusion. Am. J. Physiol. 1996; 271: G814-19.
62. Lingenfelser T, Sun W, Hebbard GS, Dent J, Horowitz M. Effects of duodenal distension on antropyloroduodenal pressures and perception are modified by hyperglycemia. Am. J. Physiol. 1999; 276: G711-18.
63. Jones KL, Horowitz M, Berry M, Wishart JM, Guha S. Blood glucose concentration influences postprandial fullness in IDDM. Diabetes Care 1997; 20: 1141-6.
64. Ma J, Rayner CK, Jones KL, Horowitz M. Insulin secretion in healthy subjects and patients with Type 2 diabetes-role of the gastrointestinal tract. Best Pract. Res. Clin. Endocrinol. Metab. 2009; 23: 413-24.
65. Horowitz M, Nauck MA. To be or not to be-an incretin or enterogastrone? Gut 2006; 55: 148-50.
66. Willms B, Werner J, Holst JJ, Orskov C, Creutzfeldt W, Nauck MA. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients. J. Clin. Endocrinol. Metab. 1996; 81: 327-32.
67. Meier JJ. The contribution of incretin hormones to the pathogenesis of type 2 diabetes. Best Pract. Res. Clin. Endocrinol. Metab. 2009; 23: 433-41.
68. Little TJ, Pilichiewicz AN, Russo A et al. Effects of intravenous glucagon-like peptide-1 on gastric emptying and intragastric distribution in healthy subjects: relationships with postprandial glycemic and insulinemic responses. J. Clin. Endocrinol. Metab. 2006; 91: 1916-23.
69. Meier JJ, Nauck MA. Is the diminished incretin effect in type 2 diabetes just an epi-phenomenon of impaired beta-cell function? Diabetes 2010; 59: 1117-25.
70. Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1 (7-36 amide) but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J. Clin. Invest. 1993; 91: 301-7.
71. Vilsboll T, Krarup T, Madsbad S, Holst JJ. Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients. Diabetologia 2002; 45: 1111-19.
72. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care 2003; 26: 881-5.
73. Ceriello A, Hanefeld M, Leiter L et al. Postprandial glucose regulation and diabetic complications. Arch. Intern. Med. 2004; 164: 2090-5.
74. Horowitz M, Edelbroek MA, Wishart JM, Straathof JW. Relationship between oral glucose tolerance and gastric emptying in normal healthy subjects. Diabetologia 1993; 36: 857-62.
75. Ishii M, Nakamura T, Kasai F, Onuma T, Baba T, Takebe K. Altered postprandial insulin requirement in IDDM patients with gastroparesis. Diabetes Care 1994; 17: 901-3.
76. Pilichiewicz AN, Chaikomin R, Brennan IM et al. Load-dependent effects of duodenal glucose on glycemia, gastrointestinal hormones, antropyloroduodenal motility, and energy intake in healthy men. Am. J. Physiol. Endocrinol. Metab. 2007; 293: E743-53.
77. Rayner CK, Ma J, Pilichiewicz A et al. Effects of variations in duodenal glucose load on glycaemia, insulin and GLP-1 in type 2 diabetes (Abstract). Diabetologia 2009; 52: S105.
78. Meier JJ, Gallwitz B, Siepmann N et al. Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia. Diabetologia 2003; 46: 798-801.
79. O'Donovan DG, Doran S, Feinle-Bisset C et al. Effect of variations in small intestinal glucose delivery on plasma glucose, insulin, and incretin hormones in healthy subjects and type 2 diabetes. J. Clin. Endocrinol. Metab. 2004; 89: 3431-5.
80. Chaikomin R, Doran S, Jones KL et al. Initially more rapid small intestinal glucose delivery increases plasma insulin, GIP, and GLP-1 but does not improve overall glycemia in healthy subjects. Am. J. Physiol. Endocrinol. Metab. 2005; 289: E504-7.
81. Horowitz M, Jones KL, Rayner CK, Read NW. "Gastric" hypoglycaemia-an important concept in diabetes management. Neurogastroenterol. Motil. 2006; 18: 405-7.
82. Chandalia M, Garg A, Lutjohann D, von Bergmann K, Grundy SM, Brinkley LJ. Beneficial effects of high dietary fiber intake in patients with type 2 diabetes mellitus. N. Engl. J. Med. 2000; 342: 1392-8.
83. Russo A, Stevens JE, Wilson T et al. Guar attenuates fall in postprandial blood pressure and slows gastric emptying of oral glucose in type 2 diabetes. Dig. Dis. Sci. 2003; 48: 1221-9.
84. Gentilcore D, Chaikomin R, Jones KL et al. Effects of fat on gastric emptying of and the glycemic, insulin, and incretin responses to a carbohydrate meal in type 2 diabetes. J. Clin. Endocrinol. Metab. 2006; 91: 2062-7.
85. Cunningham KM, Read NW. The effect of incorporating fat into different components of a meal on gastric emptying and postprandial blood glucose and insulin responses. Br. J. Nutr. 1989; 61: 285-90.
86. Ma J, Stevens JE, Cukier K et al. Effects of a protein preload on gastric emptying, glycemia, and gut hormones after a carbohydrate meal in diet-controlled type 2 diabetes. Diabetes Care 2009; 32: 1600-2.
87. Ishii M, Nakamura T, Kasai F, Baba T, Takebe K. Erythromycin derivative improves gastric emptying and insulin requirement in diabetic patients with gastroparesis. Diabetes Care 1997; 20: 1134-7.
88. Ueno N, Inui A, Asakawa A et al. Erythromycin improves glycaemic control in patients with Type II diabetes mellitus. Diabetologia 2000; 43: 411-15.
89. Samsom M, Szarka LA, Camilleri M, Vella A, Zinsmeister AR, Rizza RA. Pramlintide, an amylin analog, selectively delays gastric emptying: potential role of vagal inhibition. Am. J. Physiol. Gastrointest. Liver Physiol. 2000; 278: G946-51.
90. Vella A, Lee JS, Camilleri M et al. Effects of pramlintide, an amylin analogue, on gastric emptying in type 1 and 2 diabetes mellitus. Neurogastroenterol. Motil. 2002; 14: 123-31.
91. Thompson RG, Pearson L, Schoenfeld SL, Kolterman OG. Pramlintide, a synthetic analog of human amylin, improves the metabolic profile of patients with type 2 diabetes using insulin. The Pramlintide in Type 2 Diabetes Group. Diabetes Care 1998; 21: 987-93.
92. Thompson RG, Gottlieb A, Organ K, Koda J, Kisicki J, Kolterman OG. Pramlintide: a human amylin analogue reduced postprandial plasma glucose, insulin, and C-peptide concentrations in patients with type 2 diabetes. Diabet. Med. 1997; 14: 547-55.
93. Linnebjerg H, Park S, Kothare PA et al. Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes. Regul. Pept. 2008; 151: 123-9.
94. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006; 368: 1696-705.
95. Vella A, Bock G, Giesler PD et al. The effect of dipeptidyl peptidase-4 inhibition on gastric volume, satiation and enteroendocrine secretion in type 2 diabetes: a double-blind, placebo-controlled crossover study. Clin. Endocrinol. (Oxf) 2008; 69: 737-44.
96. O'Donovan D, Feinle-Bisset C, Jones K, Horowitz M. Idiopathic and Diabetic Gastroparesis. Curr. Treat. Options. Gastroenterol. 2003; 6: 299-309.
97. Olausson EA, Alpsten M, Larsson A, Mattsson H, Andersson H, Attvall S. Small particle size of a solid meal increases gastric emptying and late postprandial glycaemic response in diabetic subjects with gastroparesis. Diabet. Res. Clin. Pract. 2008; 80: 231-7.
98. Khoo J, Rayner CK, Jones KL, Horowitz M. Pathophysiology and management of gastroparesis. Expert Rev. Gastroenterol. Hepatol. 2009; 3: 167-81.
99. Sturm A, Holtmann G, Goebell H, Gerken G. Prokinetics in patients with gastroparesis: a systematic analysis. Digestion 1999; 60: 422-7.
100. Tonini M, De Ponti F, Di Nucci A, Crema F. Review article: cardiac adverse effects of gastrointestinal prokinetics. Aliment. Pharmacol. Ther. 1999; 13: 1585-91.
101. Takanashi H, Cynshi O. Motilides: a long and winding road: lessons from mitemcinal (GM-611) on diabetic gastroparesis. Regul. Pept. 2009; 155: 18-23.
102. Ejskjaer N, Vestergaard ET, Hellstrom PM et al. Ghrelin receptor agonist (TZP-101) accelerates gastric emptying in adults with diabetes and symptomatic gastroparesis. Aliment. Pharmacol. Ther. 2009; 29: 1179-87.
103. Murray CD, Martin NM, Patterson M et al. Ghrelin enhances gastric emptying in diabetic gastroparesis: a double blind, placebo controlled, crossover study. Gut 2005; 54: 1693-8.
104. Arts J, Holvoet L, Caenepeel P et al. Clinical trial: a randomized-controlled crossover study of intrapyloric injection of botulinum toxin in gastroparesis. Aliment. Pharmacol. Ther. 2007; 26: 1251-8.
105. Friedenberg FK, Palit A, Parkman HP, Hanlon A, Nelson DB. Botulinum toxin A for the treatment of delayed gastric emptying. Am. J. Gastroenterol. 2008; 103: 416-23.
106. Lacy BE, Zayat EN, Crowell MD, Schuster MM. Botulinum toxin for the treatment of gastroparesis: a preliminary report. Am. J. Gastroenterol. 2002; 97: 1548-52.
107. Miller LS, Szych GA, Kantor SB et al. Treatment of idiopathic gastroparesis with injection of botulinum toxin into the pyloric sphincter muscle. Am. J. Gastroenterol. 2002; 97: 1653-60.
108. Rayner CK, Horowitz M. New management approaches for gastroparesis. Nat. Clin. Pract. Gastroenterol. Hepatol. 2005; 2: 454-62. quiz 93.
109. McCallum RW, Chen JD, Lin Z, Schirmer BD, Williams RD, Ross RA. Gastric pacing improves emptying and symptoms in patients with gastroparesis. Gastroenterology 1998; 114: 456-61.
110. O'Grady G, Egbuji JU, Du P, Cheng LK, Pullan AJ, Windsor JA. High-frequency gastric electrical stimulation for the treatment of gastroparesis: a meta-analysis. World J. Surg. 2009; 33: 1693-701.
111. Abell T, Lou J, Tabbaa M, Batista O, Malinowski S, Al-Juburi A. Gastric electrical stimulation for gastroparesis improves nutritional parameters at short, intermediate, and long-term follow-up. JPEN J. Parenter. Enteral. Nutr. 2003; 27: 277-81.
112. McCallum R, Brody F, Parkman HP et al. Enterra gastric electrical stimulation for diabetic gastroparesis: results from a multicenter randomized study. Gastroenterology 2009; 136: A61-2.
113. Ejskjaer NT, Bradley JL, Buxton-Thomas MS et al. Novel surgical treatment and gastric pathology in diabetic gastroparesis. Diabet. Med. 1999; 16: 488-95.
114. Jones MP, Maganti K. A systematic review of surgical therapy for gastroparesis. Am. J. Gastroenterol. 2003; 98: 2122-9.
115. Gaber AO, Oxley D, Karas J et al. Changes in gastric emptying in recipients of successful combined pancreas-kidney transplants. Dig. Dis. 1991; 9: 437-43.